MCID: URN009
MIFTS: 51

Urinary System Disease

Categories: Cancer diseases, Nephrological diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Urinary System Disease

MalaCards integrated aliases for Urinary System Disease:

Name: Urinary System Disease 11 14 16
Abnormality of the Urinary System 28 5
Congenital Malformation of the Urinary System 71
Non-Neoplastic Urinary System Disorder 71
Non-Neoplastic Urinary Tract Disease 11
Urinary Tract Diseases 53
Urinary Tract Disease 11
Urinary Tract Anomaly 53
Urologic Diseases 71

Classifications:



External Ids:

Disease Ontology 11 DOID:18
NCIt 49 C27599
UMLS 71 C0042075 C0158698 C1335051

Summaries for Urinary System Disease

Disease Ontology: 11 A disease of anatomical entity that is located in kidney, ureter, bladder and urethra.

MalaCards based summary: Urinary System Disease, also known as abnormality of the urinary system, is related to bladder disease and kidney disease, and has symptoms including dysuria, polyuria and urgency of micturition. An important gene associated with Urinary System Disease is B2M (Beta-2-Microglobulin), and among its related pathways/superpathways are miRNAs involved in DNA damage response and Cell differentiation - expanded index. The drugs Levoleucovorin and Bupivacaine have been mentioned in the context of this disorder. Affiliated tissues include kidney, prostate and brain.

Related Diseases for Urinary System Disease

Diseases related to Urinary System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 453)
# Related Disease Score Top Affiliating Genes
1 bladder disease 32.5 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
2 kidney disease 32.5 UMOD SIX1 NAGLU MIR21 MIR199A1 B2M
3 urinary tract infection 32.4 UMOD KLK3 H2AC18 CFHR2 CCR6
4 ureteral disease 32.4 UMOD MIR199A1 MIR142 CCR6
5 urinary tract obstruction 31.1 UMOD NAGLU MIR199A1 MIR142 KLK3 CCR6
6 vesicoureteral reflux 31.1 UMOD SIX1 NAGLU B2M
7 bladder cancer 31.0 MIR21 MIR199A1 MIR17 MIR145 KRT20 KLK3
8 lymphoma, non-hodgkin, familial 30.8 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
9 mycobacterium tuberculosis 1 30.7 MIR21 MIR155 MIR144 ICOSLG H2AC18 CCR6
10 viral infectious disease 30.7 MIR21 MIR199A1 MIR155 ICOSLG H2AC18 CCR6
11 wilms tumor 1 30.7 SIX1 MIR199A1 MIR193A MIR144 MIR142 ICOSLG
12 endometriosis 30.7 MIR199A1 MIR17 MIR145 MIR142 MIR126
13 hydronephrosis 30.7 NAGLU KLK3 B2M
14 acute kidney tubular necrosis 30.7 UMOD NAGLU CCR6 B2M
15 chronic kidney disease 30.7 UMOD MIR21 MIR126 CFHR2 CCR6 B2M
16 dermatitis, atopic 30.7 MIR21 MIR155 MIR142 ICOSLG CCR6
17 deficiency anemia 30.7 MIR126 ICOSLG H2AC18 CFHR2 CCR6 B2M
18 syphilis 30.6 MIR142 CCR6 B2M
19 cervical cancer 30.5 MIR30A MIR21 MIR193A MIR17 MIR155
20 hematuria, benign familial 11.0
21 cakut 11.0
22 urolithiasis 11.0
23 urethral syndrome 11.0
24 bacteriuria 11.0
25 lower urinary tract calculus 11.0
26 lung cancer 10.7 SIX1 MIR30A MIR21 MIR199A1 MIR193A MIR17
27 nervous system disease 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
28 type 2 diabetes mellitus 10.7 NAGLU MIR30A MIR21 MIR199A1 MIR193A MIR17
29 peripheral nervous system disease 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
30 leukocyte disease 10.7 MIR30A MIR21 MIR199A1 MIR17 MIR155 MIR145
31 bone marrow cancer 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
32 renal cell carcinoma, nonpapillary 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
33 leukemia, chronic lymphocytic 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
34 squamous cell carcinoma, head and neck 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
35 biliary tract disease 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
36 esophageal disease 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
37 bone disease 10.7 MIR30A MIR21 MIR199A1 MIR17 MIR155 MIR142
38 bile duct adenocarcinoma 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
39 ovary epithelial cancer 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
40 skin disease 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
41 bile duct disease 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
42 kidney cancer 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
43 autonomic nervous system neoplasm 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
44 malignant exocrine pancreas neoplasm 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
45 lung cancer susceptibility 3 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
46 pancreatic ductal adenocarcinoma 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
47 head and neck cancer 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
48 peripheral nervous system neoplasm 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
49 male reproductive system disease 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
50 upper respiratory tract disease 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155

Graphical network of the top 20 diseases related to Urinary System Disease:



Diseases related to Urinary System Disease

Symptoms & Phenotypes for Urinary System Disease

UMLS symptoms related to Urinary System Disease:


dysuria; polyuria; urgency of micturition; other and unspecified genitourinary symptoms; renal colic; pain in urethra; uti symptoms; urethral burning on micturition; loin pain; ureteral pain; flank tenderness; difficulty passing urine; urinary tenesmus; burning urination; bladder discomfort; renal pain; urologic problem

Drugs & Therapeutics for Urinary System Disease

Drugs for Urinary System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 174)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
2
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
3
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
4
Uric acid Investigational Phase 4 69-93-2 1175
5 Folate Phase 4
6 Vitamin B9 Phase 4
7 Vitamin B Complex Phase 4
8 Vitamins Phase 4
9 Trace Elements Phase 4
10 Hematinics Phase 4
11 Micronutrients Phase 4
12 Anesthetics, Local Phase 4
13 Analgesics, Opioid Phase 4
14 Narcotics Phase 4
15
Tamsulosin Approved, Investigational Phase 3 106133-20-4 129211
16
Mirabegron Approved Phase 3 223673-61-8 18319735 9865528
17
Pregabalin Approved, Investigational Phase 3 148553-50-8 5486971
18
Lomefloxacin Approved, Investigational Phase 3 98079-51-7 3948
19
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
20
Ofloxacin Approved Phase 3 82419-36-1 4583
21
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1, 93107-08-5 2764
22
Propiverine Approved, Investigational Phase 3 60569-19-9 4942
23 Anti-Bacterial Agents Phase 3
24 Anti-Infective Agents Phase 3
25 Cytochrome P-450 Enzyme Inhibitors Phase 3
26 Adrenergic beta-Agonists Phase 3
27 Adrenergic beta-3 Receptor Agonists Phase 3
28 Adrenergic Agonists Phase 3
29 Adrenergic Agents Phase 3
30
Solifenacin Succinate Phase 3 242478-38-2 216457
31 Muscarinic Antagonists Phase 3
32 Cholinergic Antagonists Phase 3
33 Cholinergic Agents Phase 3
34 Anti-Anxiety Agents Phase 3
35 calcium channel blockers Phase 3
36 Analgesics Phase 3
37 Parasympatholytics Phase 3
38 Pharmaceutical Solutions Phase 2, Phase 3
39
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
40
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
41
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
42
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
43
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4 254741536
44 Antibiotics, Antitubercular Phase 2
45 Neurotransmitter Agents Phase 2
46 Alkylating Agents Phase 2
47 Albumin-Bound Paclitaxel Phase 1, Phase 2
48 Antimitotic Agents Phase 1, Phase 2
49 Tubulin Modulators Phase 1, Phase 2
50 Immunoglobulins Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 136)
# Name Status NCT ID Phase Drugs
1 Periprocedural Administration of Folic Acid for Prevention of Contrast Induced Nephropathy in Patients Undergoing Coronary CTA/Angiography/Angioplasty Unknown status NCT02444013 Phase 4 Folic acid;Placebo
2 Efficacy of the Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures Completed NCT02805504 Phase 4 Exparel;Marcaine
3 A Randomized Trial Evaluating Use of Long-Acting Liposomal Bupivacaine (Exparel®) in Reducing Narcotic Pain Requirements in Pediatric Patients Undergoing Minor Urologic Procedures Recruiting NCT04826484 Phase 4 Exparel 133 miligrams per 10 milliliter injection;Bupivacaine Hydrochloride
4 Does Depth of Neuromuscular Blockade (NMB) Affect Surgical Conditions and Postoperative Pain in Obese Patients Undergoing Robotic Surgery Withdrawn NCT03591289 Phase 4 NMB with rocuronium bromide
5 Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome Completed NCT00239317 Phase 3 Tamusulosin
6 Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome Completed NCT00239265 Phase 3 Tamuslosin
7 A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms Completed NCT01908829 Phase 3 mirabegron 25 mg;mirabegron 50 mg;solifenacin 5 mg;solifenacin 10 mg;mirabegron 25 mg matching placebo;mirabegron 50 mg matching placebo;solifenacin 5 mg matching placebo;solifenacin 10 mg matching placebo
8 Perioperative Pregabalin as Part of a Multimodal Treatment Plan for Pain After Ureteroscopy With Stent Placement: a Pilot Completed NCT03927781 Phase 3 Pregabalin 300mg
9 A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder Completed NCT02045862 Phase 3 Solifenacin succinate;Mirabegron;Placebo to match solifenacin;Placebo to match mirabegron
10 A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder Completed NCT01972841 Phase 3 Solifenacin succinate;Mirabegron;Placebo to match solifenacin succinate;Placebo to match mirabegron
11 A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy Completed NCT01638000 Phase 3 Mirabegron;Solifenacin succinate
12 A Multicenter, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Lomefloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults Completed NCT00258102 Phase 3 Levofloxacin
13 A Multicenter, Double-Blind, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Ciprofloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults Completed NCT00258089 Phase 3 Levofloxacin
14 Efficacy and Tolerability of Propiverine Hydrochloride Extended Release (ER) Compared to Immediate Release (IR) in Patients With Neurogenic Detrusor Overactivity. A Randomized, Double Blind, Parallel Group, Multicenter Clinical Trial Completed NCT01530620 Phase 3 Propiverine hydrochloride ER (extended release);Propiverine hydrochloride IR (immediate release)
15 The Outcomes of Intracavernosal Umbilical Cord Mesenchymal Stem Cells Implantation in Patients With Diabetic Erectile Dysfunction Recruiting NCT04972890 Phase 2, Phase 3
16 An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria Enrolling by invitation NCT04042402 Phase 3 DCR-PHXC
17 A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB) Terminated NCT00384891 Phase 3 Bacillus Calmette-Guérin
18 A Multi-Centre, Randomised, Open-Label Active-Controlled Study Comparing Safety and Efficacy of Synergo Radiofrequency (RF)-Induced Hyperthermia-Chemotherapy With Mitomycin C (RITE) Versus Bacillus Calmette-Guérin (BCG) as First-Line Treatment of Non-Muscle Invasive Papillary Bladder Cancer (NMIBC) Withdrawn NCT02254915 Phase 3 Bacillus Calmette-Guérin
19 Evaluation of the Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel Mixed With Mitomycin C (MMC) in Non-muscle Invasive Bladder Cancer (NMIBC) Patients Completed NCT02307487 Phase 2 120 mg MMC in 90ml gel;140 mg MMC in 90ml gel;160 mg MMC in 90ml gel;120 mg MMC in 60ml gel;140 mg MMC in 60ml gel;160 mg MMC in 60ml gel
20 Muscle Cell Mediated Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery: An Investigation of Cook MyoSite Autologous Muscle Derived Cells Completed NCT02291432 Phase 1, Phase 2
21 Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention Completed NCT04555343 Phase 1, Phase 2 Tranexamic acid
22 A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer Completed NCT03081858 Phase 1, Phase 2 TSD-001
23 A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria Completed NCT03847909 Phase 2 DCR-PHXC;Sterile Normal Saline (0.9% NaCl)
24 A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of Female Patients With Bladder Pain Syndrome / Interstitial Cystitis Completed NCT01613586 Phase 2 ASP3652;Placebo
25 A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder. Completed NCT01340027 Phase 2 Mirabegron;Solifenacin succinate;Placebo
26 Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II. Completed NCT03562897 Phase 2
27 A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease Terminated NCT04387448 Phase 2 GFB-887;Placebo
28 A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Interstitial Cystitis/ Painful Bladder Syndrome Terminated NCT01060254 Phase 2 Placebo;JNJ-42160443
29 A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects With Locally Advanced or Metastatic Urothelial Cell Carcinoma Who Have Relapsed After, or Are Refractory to Standard Therapy Terminated NCT02401542 Phase 1, Phase 2 Vofatamab;Docetaxel;Placebo
30 A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined With Pembrolizumab in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Who Have Progressed Following Platinum-based Chemotherapy Terminated NCT03123055 Phase 1, Phase 2 B-701;Pembrolizumab
31 An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases Terminated NCT04950114 Phase 2 GFB-887
32 A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fasted State in Healthy Adult Male Subjects Completed NCT02052713 Phase 1 Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg;Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
33 A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fed State in Healthy Adult Male Subjects Completed NCT02058576 Phase 1 Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg;Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
34 Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients Completed NCT01232010 Phase 1 Mirodenafil
35 Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients Completed NCT01231997 Phase 1 Udenafil
36 Pilot Study of Mycophenolate Mofetil in Congenital Uropathies Completed NCT00193635 Phase 1 mycophenolate mofetil
37 Perioperative Testosterone Replacement Therapy Improves Outcomes: A Pilot Safety and Feasibility Study Recruiting NCT04731376 Phase 1 Testosterone Cypionate
38 Safety and Clinical Outcomes Study: Amniotic and Umbilical Cord Tissue Administration for Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions Not yet recruiting NCT03899298 Phase 1
39 A Phase 1 Pilot Safety and Feasibility Study of Autologous Engineered Urethral Not yet recruiting NCT03258658 Phase 1
40 Phase 1 Pilot Study of Bioengineered Penile Tissue Constructs in Subjects With Irreversibly Damaged Penile Corpora Not yet recruiting NCT03463239 Phase 1
41 A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma Terminated NCT02386111 Phase 1 Combination of varlilumab and sunitinib
42 A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer Terminated NCT02543645 Phase 1 Combination of Varlilumab and Atezolizumab
43 The Effectiveness of Virtual Reality (VR) to Reduce Pain and Anxiety During Genitourinary (GU) Scans Unknown status NCT04251988
44 Effectiveness of Drainage of the Kidney by Percutaneous Nephrostomy Catheter Placement Vs. Retrograde Double J Catheter Placement in Patients With Symptoms of Obstructive Kidney Disease Caused by Urolithiasis Unknown status NCT04594161
45 Bladder Morphology Using 2 Different Catheter Designs Foley Catheter vs. Cystosure Urinary Access System Unknown status NCT03108079
46 Pharmacology and Physiology of the Lower Urinary Tract Unknown status NCT00662064
47 Patient Empowerment for Major Surgery Preparation @ Home: Multimodal Prehabilitation in Major Elective Surgery Unknown status NCT04190719
48 The Utility of Enhanced Pre- and Post-surgical Protocols to Prevent the Spread of COVID-19 in a Large Urological Department (UroCovid Study) Unknown status NCT04409899
49 Remote Ischemic Conditioning (RIC) to Decrease Post-Operative Complications After Major Abdominal Surgery - A Phase IIa Trial Unknown status NCT03234543
50 The Alternating Bidirectional Versus The Standard Approach During Shock Wave Lithotripsy For Renal And Upper Lumbar Ureteric Stones. A Randomized Clinical Trial Unknown status NCT03243682

Search NIH Clinical Center for Urinary System Disease

Genetic Tests for Urinary System Disease

Genetic tests related to Urinary System Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Urinary System 28

Anatomical Context for Urinary System Disease

Organs/tissues related to Urinary System Disease:

FMA: Kidney
MalaCards : Kidney, Prostate, Brain, Spinal Cord, Smooth Muscle, Heart, Neutrophil

Publications for Urinary System Disease

Articles related to Urinary System Disease:

(show top 50) (show all 1166)
# Title Authors PMID Year
1
Thyroidization in renal allografts. 53 62
19594588 2009
2
[Implications of beta 2-microglobulin in the detection of associated urinary tract diseases in patients with infiltrative pulmonary tuberculosis]. 53 62
12577571 2002
3
Urine detection of survivin and diagnosis of bladder cancer. 53 62
11176843 2001
4
[Urinary Tamm-Horsfall protein coating of free cells and its clinical diagnostic significance]. 53 62
1864173 1991
5
Biomarkers in Urethral Stricture Disease and Benign Lower Urinary Tract Disease. 62
36424081 2023
6
Increased kidney disease mortality among people with AIDS versus the general population: a population-based cohort study in Italy, 2006-2018. 62
36456002 2022
7
Investigation of the effects of three different generations of fluoroquinolone derivatives on antioxidant and immunotoxic enzyme levels in different rat tissues. 62
34601990 2022
8
Urinary Microbiome of Reproductive-Age Asymptomatic European Women. 62
36383025 2022
9
Exertional hemolysis and hematuria in a Labrador Retriever dog. 62
36184929 2022
10
Comparison of bidirectional barbed versus conventional monofilament suture material for closure of feline perineal urethrostomies. 62
36325412 2022
11
Short-term exposure to ozone and cause-specific mortality risks and thresholds in China: Evidence from nationally representative data, 2013-2018. 62
36470122 2022
12
Comparative evaluation of selected serum and urine biomarkers in cats with interstitial and bacterial cystitis. 62
36345051 2022
13
Diagnostic effectiveness of stress biomarkers in cats with feline interstitial and bacterial cystitis. 62
36436835 2022
14
Tissue S100/calgranulin expression and blood neutrophil-to-lymphocyte ratio (NLR) in dogs with lower urinary tract urothelial carcinoma. 62
36411489 2022
15
Critical size of kidney stone through ureter: A mechanical analysis. 62
36115174 2022
16
Factors associated with low-compliance bladder in end-stage renal disease patients and development of a clinical prediction model for urodynamic evaluation: the DUDi score. 62
36307573 2022
17
Urinary interleukin-6 is a potentially useful diagnostic and prognostic marker of acute kidney injury in dogs. 62
36030370 2022
18
Chromatographic Techniques and Pharmacological Analysis as a Quality Control Strategy for Serjania triquetra a Traditional Medicinal Plant. 62
36297401 2022
19
Use of feeding tubes in 112 cats in an internal medicine referral service (2015-2020). 62
35833503 2022
20
Protocol for the generation and expansion of human iPS cell-derived ureteric bud organoids. 62
35769929 2022
21
The Effect of Patient Positioning on Ureteral Efflux During Intraoperative Cystoscopy: a Randomized Controlled Trial. 62
36103970 2022
22
Prospective comparison of prostatic aspirate culture and cystocentesis urine culture for detection of bacterial infection in dogs with prostatic neoplasia. 62
36167434 2022
23
Multiple Post-SARS-COV2 Infectious Complications in Kidney Transplant Recipient. 62
36295531 2022
24
Clinical presentation, videourodynamic characteristics, and treatment outcome in men with interstitial cystitis-like lower urinary tract symptoms. 62
35804206 2022
25
How Did SARS-CoV-2 Pandemic Affect the Cats' Health in Hatay Province? A retrospective study. 62
35918018 2022
26
"Parenteral" Diarrhea Associated With Pediatric Urinary Tract Infections: A Retrospective Chart Review. 62
35413044 2022
27
Urinary culture sensitivity after a single empirical antibiotic dose for upper or febrile urinary tract infection: A prospective multicentre observational study. 62
35289297 2022
28
A multicenter study of antimicrobial prescriptions for cats diagnosed with bacterial urinary tract disease. 62
34709080 2022
29
Combination of Ligustri Lucidi Fructus with Ecliptae Herba and their phytoestrogen or phytoandrogen like active pharmaceutical ingredients alleviate oestrogen/testosterone-induced benign prostatic hyperplasia through regulating steroid 5-α-reductase. 62
35636178 2022
30
Alterations of selected serum biochemical and urinary parameters in dogs with chronic enteropathy. 62
36118717 2022
31
The Urogenital System's Role in Diseases: A Synopsis. 62
35884388 2022
32
Clinical Application of Botulinum Neurotoxin in Lower-Urinary-Tract Diseases and Dysfunctions: Where Are We Now and What More Can We Do? 62
35878235 2022
33
Fluoxetine-induced urinary retention in a cat. 62
35966899 2022
34
A nomogram model predicting the risk of postpartum stress urinary incontinence in primiparas: A multicenter study. 62
35779903 2022
35
Ethnobotany of medicinal plants used by the Yao people in Gongcheng County, Guangxi, China. 62
35729593 2022
36
Endogenous Fungal Endophthalmitis: Causative Organisms, Treatments, and Visual Outcomes. 62
35736124 2022
37
Obstructed hemivagina with ipsilateral renal and urinary tract anomaly presenting as an unusual cause of acute abdomen: a radiologic perspective. 62
35760501 2022
38
Clinical use and complications of percutaneous cystostomy pigtail catheters in 25 cats. 62
35363097 2022
39
Outcomes and postoperative complications after transpelvic urethrostomy used as first-line surgery in 38 male cats with obstructive lower urinary tract disease. 62
34431736 2022
40
Small ruminant urinary obstruction: decision trees for treatment. 62
35442905 2022
41
Ureteral Endoscopy to Detect Upper Urinary Tract Diseases in Horses. 62
35172197 2022
42
Proximity to petrochemical industrial parks and risk of chronic glomerulonephritis. 62
35016869 2022
43
Investigation of the Relationship between Colistin Resistance and Capsule Serotypes in Carbapenem Resistant Klebsiella pneumoniae Strains. 62
35699561 2022
44
Dual-Energy CT applications in urinary tract cancers: an update. 62
35442120 2022
45
[Incidence and cause of abnormal cholesterol in children aged 2-18 years in a single center]. 62
35435182 2022
46
Epidemiological investigations on microbial infection and crystals causing feline lower urinary tract disease in tomcats in Ismailia, Egypt. 62
35603074 2022
47
Ultrasonographic detection of apex nodules in the urinary bladder of Scottish Terriers. 62
34989093 2022
48
Stem Cell Application for Stress Urinary Incontinence: from Bench to Bedside. 62
35249506 2022
49
Acute-phase proteins in cats with obstructive feline lower urinary tract disease. 62
35191061 2022
50
Prevalence of positive urine culture in the presence of inactive urine sediment in 1049 urine samples from dogs. 62
35108434 2022

Variations for Urinary System Disease

ClinVar genetic disease variations for Urinary System Disease:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CHD1L NM_004284.6(CHD1L):c.234C>T (p.Thr78=) SNV Uncertain Significance
625178 rs1311096135 GRCh37: 1:146724384-146724384
GRCh38: 1:147252729-147252729

Expression for Urinary System Disease

Search GEO for disease gene expression data for Urinary System Disease.

Pathways for Urinary System Disease

Pathways related to Urinary System Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.16 MIR21 MIR17 MIR145
2
Show member pathways
11.15 MIR199A1 MIR17 MIR155 MIR145
3 10.81 MIR21 MIR199A1 MIR155 MIR145 MIR126

GO Terms for Urinary System Disease

Cellular components related to Urinary System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.03 UMOD MIR30A MIR21 MIR199A1 MIR17 MIR144
2 RISC complex GO:0016442 9.58 MIR30A MIR21 MIR199A1 MIR17 MIR155 MIR145
3 extracellular vesicle GO:1903561 9.35 MIR30A MIR21 MIR193A MIR17 MIR126

Biological processes related to Urinary System Disease according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.88 MIR21 MIR199A1 MIR17 MIR155 MIR144
2 positive regulation of angiogenesis GO:0045766 9.8 MIR30A MIR21 MIR199A1 MIR126
3 negative regulation of angiogenesis GO:0016525 9.72 MIR21 MIR193A MIR145 KLK3
4 negative regulation of inflammatory response GO:0050728 9.67 MIR199A1 MIR145 MIR142 MIR126
5 miRNA-mediated gene silencing GO:0035195 9.58 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
6 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.46 MIR199A1 MIR17
7 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.43 MIR21 MIR17
8 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.43 MIR145 MIR199A1 MIR21
9 positive regulation of metalloendopeptidase activity GO:1904685 9.4 MIR21 MIR17
10 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.35 MIR21 MIR17 MIR145 MIR144 MIR126
11 positive regulation of cellular response to hypoxia GO:1900039 9.16 MIR21 MIR145

Molecular functions related to Urinary System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.65 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
2 mRNA base-pairing translational repressor activity GO:1903231 9.32 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155

Sources for Urinary System Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....